Compounds > (e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide
Page last updated: 2024-09-04

(e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide and Autosomal Dominant Juvenile Parkinson Disease

(e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Allahtavakoli, M; Asadi-Shekaari, M; Esmaeli-Mahani, S; Nazeri, M; Razavinasab, M; Shabani, M; Shamsizadeh, A; Sheibani, V1

Other Studies

1 other study(ies) available for (e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide and Autosomal Dominant Juvenile Parkinson Disease

ArticleYear
Pharmacological blockade of TRPV1 receptors modulates the effects of 6-OHDA on motor and cognitive functions in a rat model of Parkinson's disease.
    Fundamental & clinical pharmacology, 2013, Volume: 27, Issue:6

    Topics: Acrylamides; Animals; Bridged Bicyclo Compounds, Heterocyclic; Cognition; Disease Models, Animal; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; TRPV Cation Channels

2013